<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740996</url>
  </required_header>
  <id_info>
    <org_study_id>NCT123</org_study_id>
    <nct_id>NCT04740996</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China</brief_title>
  <official_title>A Prospective Registration Study of Pembrolizumab in the First Line Therapy for PD-L1 CPS≥20 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shi Yuankai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is main evaluate the efficacy and safety of pembrolizumab in the first-line&#xD;
      treatment of Chinese patients with recurrent or metastatic head and neck squamous cell&#xD;
      carcinoma with PD-L1 CPS≥20.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a single-center, prospective phase II clinical study, which mainly evaluates&#xD;
      the efficacy and safety of first-line treatment with pembrolizumab in patients with recurrent&#xD;
      and/or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20 in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the objective response rate (ORR, RECIST standard 1.1 evaluation) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20</description>
  </primary_outcome>
  <primary_outcome>
    <measure>survival time (OS)</measure>
    <time_frame>1year</time_frame>
    <description>To evaluate the survival time (OS) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate(ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the objective response rate of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20 (ORR, iRECIST standard evaluation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the disease control rate (DCR) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the duration of response (DOR) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS ≥ 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS, PFS2)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the progression-free survival (PFS, PFS2) of patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS ≥ 20 in the first-line treatment of Pembrolizumab;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>TMB, T cell gene expression</measure>
    <time_frame>3 year</time_frame>
    <description>Correlation between the results of TMB and inflammatory T cell gene expression profiles in tumor tissues of baseline patients and the efficacy and prognosis.</description>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.</description>
    <other_name>keytruda</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recurrent and/or metastatic head and neck squamous cell carcinoma who are&#xD;
        about to receive advanced first-line treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign a written informed consent before screening;&#xD;
&#xD;
          2. Male or female, aged ≥18 years old;&#xD;
&#xD;
          3. ECOG physical status score 0-1 points;&#xD;
&#xD;
          4. Head and neck squamous cell carcinoma (HNSCC) confirmed by histology or cytology, the&#xD;
             primary site is oral cavity, oropharynx, hypopharynx or larynx;&#xD;
&#xD;
          5. Recurrent and/or metastatic HNSCC without indications for local radical treatment;&#xD;
&#xD;
          6. According to the evaluation criteria for the efficacy of solid tumors (RECIST version&#xD;
             1.1), there is at least one measurable lesion. For lesions that have received&#xD;
             radiotherapy in the past, they can only be selected as the disease if there is a clear&#xD;
             disease progression 3 months after the end of radiotherapy. Target lesion&#xD;
&#xD;
          7. PD-L1 immunohistochemical detection of tumor tissue samples with CPS≥20;&#xD;
&#xD;
          8. The expected survival period exceeds 3 months;&#xD;
&#xD;
          9. The main organs function normally, that is, they meet the following standards:&#xD;
&#xD;
             i. Routine blood test (not receiving blood transfusion, erythropoietin (EPO),&#xD;
             granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony&#xD;
             stimulating factor (GM-CSF) within 14 days before the screening examination) :&#xD;
             Neutrophils ≥1.5×109/L, platelets ≥100×109/L, hemoglobin ≥90g/L; ii. Liver function:&#xD;
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ALT and AST≤3×ULN&#xD;
             for those without liver metastasis, ALT and AST≤5×ULN for those with liver metastasis;&#xD;
             total bilirubin (TBIL)≤ 1.5×ULN (Patients with Gilbert syndrome, ≤3×ULN); iii. Renal&#xD;
             function: serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (Ccr) ≥50ml/min; iv.&#xD;
             Coagulation function: activated partial thromboplastin time (APTT), international&#xD;
             normalized ratio (INR), prothrombin time (PT)≤1.5×ULN;&#xD;
&#xD;
         10. Heart echocardiogram: left ventricular ejection fraction (LVEF) ≥50%;&#xD;
&#xD;
         11. Women should agree to use contraceptive measures (such as intrauterine device [IUD],&#xD;
             contraceptives or condoms) during the study period and 6 months after the end of the&#xD;
             study; the blood pregnancy test is negative within 7 days before the study is&#xD;
             enrolled, And must be a non-lactating patient; men should agree to patients who must&#xD;
             use contraception during the study period and within 6 months after the end of the&#xD;
             study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are suitable for local treatment and are willing to local treatment;&#xD;
&#xD;
          2. Have received systemic chemotherapy, but does not include chemotherapy for locally&#xD;
             advanced disease as a part of multimodal treatment (the end of this treatment must be&#xD;
             more than 6 months from the first trial drug); Note: Multimodal treatment includes&#xD;
             induction chemotherapy, concurrent radiotherapy and chemotherapy and adjuvant&#xD;
             chemotherapy.&#xD;
&#xD;
          3. Locally advanced head and neck squamous cell carcinoma multimodal treatment is&#xD;
             completed within 6 months of disease progression;&#xD;
&#xD;
          4. Have previously been immunized with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or&#xD;
             anti-CTLA-4 antibodies or any other antibodies or drugs that target T cell&#xD;
             co-stimulation or immune checkpoint pathways treatment;&#xD;
&#xD;
          5. Other malignant tumors occurred within 5 years or at the same time during the current&#xD;
             period, except for cured cervical carcinoma in situ, non-melanoma skin cancer, or&#xD;
             other tumors/cancers that have undergone radical treatment and have no signs of&#xD;
             disease for at least 5 years;&#xD;
&#xD;
          6. Received cetuximab treatment within 6 months before the first administration;&#xD;
&#xD;
          7. According to the standard of common adverse event term (NCI CTCAEv5.0), peripheral&#xD;
             neuropathy has been ≥2 grade;&#xD;
&#xD;
          8. Accompanied by known active central nervous system metastasis (CNS) and/or cancerous&#xD;
             meningitis: Subjects with brain metastases who have received previous treatment can&#xD;
             participate in the study, provided that they are clinically stable for at least 2&#xD;
             weeks and there are no new or expanded ones Evidence of brain metastases, and steroids&#xD;
             were stopped 14 days before study drug administration. Stable brain metastases in this&#xD;
             definition should be determined before the first administration of the study drug.&#xD;
             Subjects with asymptomatic brain metastases (that is, no neurological symptoms, no&#xD;
             corticosteroids, and no lesions&gt; 1.5 cm) can participate, but they need to have&#xD;
             regular brain imaging examinations as the disease site;&#xD;
&#xD;
          9. Subjects who have not recovered from any acute effects of previous surgery,&#xD;
             chemotherapy or radiotherapy, that is, subjects who have not fallen to ≤1 (NCI&#xD;
             CTCAEv5.0) (except for hair loss). If the nutritional status is stable, allow the&#xD;
             chronic late toxicity (pharyngeal/laryngo toxicity, dry mouth, abnormal speech,&#xD;
             swallowing, etc.) from previous radiotherapy and/or surgery;&#xD;
&#xD;
         10. Any component of the studied drug or preparation has caused severe allergic reactions,&#xD;
             including known severe allergic reactions to other monoclonal antibodies (NCI&#xD;
             CTCAEv5.0≥3);&#xD;
&#xD;
         11. Have received anti-tumor drug therapy (such as chemotherapy, hormone therapy,&#xD;
             immunotherapy, antibody therapy, radiotherapy, etc.) 4 weeks or 4 weeks before the&#xD;
             first administration, except for palliative radiotherapy for bones to relieve pain;&#xD;
&#xD;
         12. Chinese herbal medicines or proprietary Chinese medicines that have received&#xD;
             anti-tumor treatment ≤1 week before the first administration;&#xD;
&#xD;
         13. Have received major surgery within 4 weeks before the first administration or are&#xD;
             expected to undergo major surgery during the study period;&#xD;
&#xD;
         14. Immunosuppressive drugs need to be used 2 weeks before the first administration or&#xD;
             within 2 weeks or during the study period, except for the following conditions:&#xD;
&#xD;
               1. Intranasal, inhaled, topical steroid or topical steroid injection (such as&#xD;
                  intra-articular injection);&#xD;
&#xD;
               2. Physiological dose of systemic corticosteroids (≤10mg/day prednisone or&#xD;
                  equivalent dose);&#xD;
&#xD;
               3. Short-term (≤7 days) use of steroids to prevent or treat non-autoimmune allergies&#xD;
                  Sexual disease&#xD;
&#xD;
         15. Subjects who are known to have active or have a history of autoimmune diseases that&#xD;
             are likely to relapse (such as systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             inflammatory bowel disease, autoimmune thyroid disease, Patients with multiple&#xD;
             sclerosis, vasculitis, glomerulitis, etc.), or high-risk (such as receiving an organ&#xD;
             transplant and requiring immunotherapy). However, the following patients are allowed&#xD;
             to join the group: patients with type I diabetes who are in stable condition after&#xD;
             using a fixed dose of insulin; autoimmune hypothyroidism who only needs hormone&#xD;
             replacement therapy; skin diseases that do not require systemic treatment (such as&#xD;
             eczema, which occupies body surface Less than 10% of skin rashes, psoriasis without&#xD;
             ophthalmological symptoms, etc.);&#xD;
&#xD;
         16. Subjects with known history of interstitial lung disease, history of non-infectious&#xD;
             pneumonia, or high suspicion of interstitial lung disease; subjects who have&#xD;
             previously had drug-induced or radiation non-infectious pneumonia but asymptomatic are&#xD;
             allowed to enter group;&#xD;
&#xD;
         17. History of infection with human immunodeficiency virus (positive HIV test), or other&#xD;
             acquired or congenital immunodeficiency diseases, or history of organ transplantation,&#xD;
             or history of stem cell transplantation;&#xD;
&#xD;
         18. At the time of screening, the hepatitis B or C virology test meets any of the&#xD;
             following:&#xD;
&#xD;
               1. HBsAg is positive and the titer of hepatitis B virus deoxyribonucleic acid (HBV&#xD;
                  DNA) in peripheral blood is ≥104 copies/ml or ≥2000 IU/ml;&#xD;
&#xD;
               2. HCV antibody is positive, and HCV-RNA is higher than the detection limit of the&#xD;
                  analysis method;&#xD;
&#xD;
         19. Within 2 weeks or 2 weeks before the first administration, the subject has an active&#xD;
             infection or uncontrollable infection that requires systemic treatment (except simple&#xD;
             urinary tract infection or upper respiratory tract infection);&#xD;
&#xD;
         20. Live virus vaccine has been vaccinated within 4 weeks before the first dose. Allow&#xD;
             seasonal influenza vaccination without live virus;&#xD;
&#xD;
         21. Serous effusion (such as pleural effusion and ascites) with clinical symptoms that&#xD;
             require clinical intervention or stable time less than 4 weeks;&#xD;
&#xD;
         22. Known to be accompanied by serious medical diseases, such as cardiac dysfunction of&#xD;
             grade III and above (New York Heart Association [NYHA]), cardiovascular diseases such&#xD;
             as ischemic heart disease (such as myocardial infarction or angina), or the first&#xD;
             administration A history of myocardial infarction within the first 3 months, poorly&#xD;
             controlled diabetes (fasting blood glucose ≥10mmol/L) or poorly controlled&#xD;
             hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure&#xD;
             ≥100mmHg) after drug treatment;&#xD;
&#xD;
         23. Medical or psychiatric history or laboratory abnormality history that may interfere&#xD;
             with the interpretation of results;&#xD;
&#xD;
         24. The subject is currently enrolled in another research device or research drug study,&#xD;
             or the time away from stopping other research drugs or research devices is less than&#xD;
             or equal to 4 weeks;&#xD;
&#xD;
         25. The subject is known to be addicted to alcohol or drugs;&#xD;
&#xD;
         26. The researcher believes that the subject has other conditions that may affect its&#xD;
             compliance with the protocol and the evaluation of the research indicators, and it is&#xD;
             not suitable for the subjects to participate in the research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shi Yuankai</investigator_full_name>
    <investigator_title>Director, Head of Oncology, Chief physician</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>immune therapy</keyword>
  <keyword>Pembrolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

